Monitor ISS and Glass Lewis updated recommendations following this second supplement; a favorable revision could increase passage probability for Proposal 4, removing a small overhang. If the revised plan passes, the dilution impact is lower than originally feared, but the routine nature of this supplement suggests limited near-term price impact.
ANIK drugs
ANIK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $14.60entry
- T+1 · 5mo ago −0.21%α +0.09% · $14.57
- T+5 · 5mo ago +0.07%α −2.04% · $14.61
- T+20 · 4mo ago +9.79%α +8.16% · $16.03
- T+60 · 3mo ago +44.59%α +41.54% · $21.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Anika Therapeutics filed a second supplement to its proxy statement responding to ISS's unfavorable recommendation on Proposal 4 (equity incentive plan amendment). The board reduced the requested new share increase from 475,000 to 350,000 shares, lowering estimated dilution from ~29.40% to ~24.88%, and is now seeking approval of a 'Revised Seventh Amended Plan' capping total authorized shares at 6,110,000. The matter will be voted on at the June 18, 2026 annual meeting.
Key Financial Metrics
Key Facts
- Board cut requested new shares from 475,000 to 350,000 after ISS flagged excessive dilution (estimated 29.40% fully diluted)
- Revised plan would increase total shares reserved from 5,760,000 to 6,110,000, reducing estimated dilution to ~24.88%
- Company noted ~$3.0 million in annualized savings from recent restructuring actions to support disciplined equity usage
- Three-year average burn rate is 3.92% per fiscal years 2023-2025
- Annual meeting scheduled for June 18, 2026; board unanimously recommends voting FOR the revised plan
Financial Impact
Proposed dilution reduced from ~29.4% to ~24.88% by cutting share request by 125,000 shares (26% reduction). No dollar figures for compensation or dilution impact provided.
Risk Factors
- Plan may still fail if ISS recommendation remains unfavorable despite the concession
- Dilution of ~24.88% is still relatively high and could weigh on the stock over time
- Engagement with proxy advisory firms could continue to pressure management on equity usage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-024374 |
| Document: 0001140361-26-024374-index-headers.html | 0001140361-26-024374 |
| Document: 0001140361-26-024374-index.html | 0001140361-26-024374 |
| Document: 0001140361-26-024374.txt | 0001140361-26-024374 |
Track record
13 reports on ANIK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
- Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
- Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
- Jun 8, 202623w ago DEFA14A Neutral 4/10 Viewing Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
- Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
- Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
- Apr 29, 202628w ago 8-K Mixed 6/10 Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers